C. van Herpen

Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

Paolo Bossi, Anthony T.�C. Chan, Lisa Licitra et al. · Annals of Oncology · 2020 · 424 citations · Full text

Medicine, Oncology, Otolaryngology +14

Salivary gland cancer: ESMO–European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up

C. van Herpen, Vincent Vander Poorten, Alena Skálová et al. · ESMO Open · 2022 · 184 citations · Full text

Medicine, Neck Surgery, Oncology +17

Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head andneck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971)

Jan B. Vermorken, Éva Remenár, C. van Herpen et al. · Journal of Clinical Oncology · 2004 · 93 citations

Medicine, Oncology, Cancer Pharmacology +8

Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I–II feasibility study

D. Schrijvers, C. van Herpen, Joseph Kerger et al. · Annals of Oncology · 2004 · 87 citations · Full text

Medicine, Oncology, Chemotherapy +8

EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma

Enrico Franceschi, Roger Stupp, Martin J. van den Bent et al. · Neuro-Oncology · 2012 · 62 citations · Full text

Medicine, Oncology, Pharmacokinetics +17